A5013084374- Lipoproteins and Cardiovascular Health
- Heart Failure Treatment and Management
- Hormonal Regulation and Hypertension
- Peroxisome Proliferator-Activated Receptors
- Neuropeptides and Animal Physiology
- Vitamin K Research Studies
- Cardiovascular Disease and Adiposity
- Renin-Angiotensin System Studies
- Peptidase Inhibition and Analysis
- Nitric Oxide and Endothelin Effects
- Atherosclerosis and Cardiovascular Diseases
- Vitamin C and Antioxidants Research
- Receptor Mechanisms and Signaling
- Cancer, Lipids, and Metabolism
- Antioxidant Activity and Oxidative Stress
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Cardiovascular Function and Risk Factors
- Retinoids in leukemia and cellular processes
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Estrogen and related hormone effects
- Diabetes Treatment and Management
- Mast cells and histamine
- Helicobacter pylori-related gastroenterology studies
- Plant biochemistry and biosynthesis
Novartis (Japan)
1998-2023
Novartis (Switzerland)
2002-2023
Food Research Institute
1995-2011
Novartis (Germany)
2003
Takarazuka City Hospital
1998-2000
The study aimed to investigate low-density lipoprotein cholesterol (LDL-C) goal achievement rates in patients receiving LDL-C-lowering therapy using recent real-world data, following the 2017 revision of Japan Atherosclerosis Society Guidelines for Prevention Atherosclerotic Cardiovascular Diseases (JAS GL2017).Patients with documented LDL-C test results were extracted from Medical Data Vision claims database between July 2018 and June 2021 divided into three groups according JAS GL2017:...
This study was performed to determine the effects of a high-fat diet on glucose metabolism after an oral challenge in diet-fed dipeptidyl peptidase IV (DPP-IV) positive (+) and deficient (−) Fischer 344 (F344) rats novel DPP-IV inhibitor NVP-DPP728 (1-{2-[(5-cyano-pyridin-2-yl)amino]ethylamino}acetyl-2-cyano-(S)-pyrrolidine monohydrochloride salt) tolerance F344 rats. In DPP-IV(+) rats, load caused impaired tolerance, such as increases plasma insulin blood concentrations challenge, compared...
1. The effects of fluvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the vascular angiotensin converting enzyme (ACE) activity in hyperlipidaemic rabbits were compared with those enalapril, an ACE inhibitor. 2. Rabbits fed 1.5% cholesterol containing diet or normal for 16 weeks and treated either fluvastatin enalapril at respective doses 2 10 mg kg-1 day-1. total cholesterol, triglyceride phospholipid levels serum significantly increased high diet....
Fluvastatin, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, exerts an inhibitory effect on intimal thickening after mechanical injury in normocholesterolemic rabbit artery at dose not enough to elicit known action of lipid lowering. This study was designed determine whether atherosclerotic progression triggered by hypercholesterolemia can be inhibited fluvastatin under conditions without its hypocholesterolemic effect. Rabbits were fed 0.5% cholesterol diet or normal for...
We previously reported that fluvastatin, a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, strong lipid lowering drug, exerted an anti-atherosclerotic effect at doses insufficient to lower serum lipids in cholesterol fed rabbits. The evidence demonstrated the superoxide anions from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase plays critical role several steps development of atherosclerosis. This study was designed determine effects HMG-CoA...
Our objective was to characterize cases of hospitalized heart failure (HHF) focusing on in-hospital resource utilization (particularly furosemide doses) and worsening (WHF), identify which factors are associated with the length stay (LOS). Cases HHF (≥20 years), excluding those undergoing surgical procedures deaths, were retrieved from Japanese Diagnosis Procedure Combination database (April 2012 March 2016). WHF defined using eight components, including up-titration intravenous drugs...
The aim of this study was to investigate the effects aging on glucose metabolism after oral challenge in aged dipeptidyl peptidase IV (DPP-IV) positive (+) Fischer 344 (F344), DPP-IV deficient (−) F344 and DPP-IV(+) Wistar rats determine effect a inhibitor NVP-DPP728 (1-{2-[(5-cyanopyridin-2-yl)amino]ethylamino}acetyl-2-cyano-(S)-pyrrolidine monohydrochloride salt) tolerance rats. Aging caused decrease early insulin response an or rats, but not DPP-IV(−) compared with young control groups....
Repeated hospitalization is a predictor of outcomes in heart failure, indicating the presence symptoms, deteriorated condition at pre-admission, and worsened prognosis. The current database study aimed to understand clinical economic burden repeated hospitalizations among patients with failure Japan. effect on subsequent in-hospital mortality was primary objective; after discharge investigated as secondary outcome. Between 2013 2018, administrative claims summary data aged ≥ 20 years...
The relationship between vascular angiotensin-converting enzyme (ACE) activity in the aorta and atherosclerotic lesions was investigated rabbits fed two atherogenic diets, 0.5 1.5% cholesterol, for 17 wk. Tissue ACE assessed by cleavage rate of hippuric acid from a synthetic substrate. Total triglycerides, phospholipids serum were significantly increased diet. Vascular femoral artery, abdominal aorta, aortic arch (2-5 times) diet high-cholesterol-related manner compared with normal increase...
Recent evidence suggests that the beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on entothelial function and cardiovascular ischemic events may be attributed not only to their lipid-lowering but also cholesterol-lowering independent (direct) atherosclerotic vessel wall. This study was designed test hypothesis fluvastatin (Flu) preserves endothelial by its actions. Rabbits were fed a 0.5% high-cholesterol (HC) diet for 12 weeks (progression phase) then HC...
Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor cholesteryl ester transfer protein (CETP) with core structure distinct from other reported CETP inhibitors. A versatile synthesis starting 4-methoxypyridine enabled an efficient exploration SAR, giving lead molecule potent inhibition in human plasma. The subsequent optimization focused on improvement pharmacokinetics mitigation off-target liabilities, such as CYP inhibition, whose correlated...
The aim of this cross-sectional survey was to characterize the role and burden on caregivers heart failure (HF) patients in Japan, since such data are limited at present. Data from 126 whose average age 63.5 years were analyzed. Helping prepare meals/cooking most frequently reported activity (47% caregivers); 24% found burdensome. physical consequence caregiving feeling physically tired (44%); emotionally worrying about patient (62%) frequent psychological consequence. Approximately half...
Background:We investigated the impact of heart failure (HF) on daily life and satisfaction with current HF medication from patient perspective in a real-world study Japan.
ABSTRACT Fluvastatin, the first totally synthetic inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, has unique structure a mevalonolactone derivative fluorophenyl‐substituted indole ring. Fluvastatin markedly reduces plasma lipid levels in animals and humans by inhibiting activity HMG‐CoA reductase following up‐regulation low density lipoprotein receptors, as it occurs with other inhibitors. Several lines evidence indicate that hypolipidemic action fluvastatin results...
This study was designed to test the hypothesis that fluvastatin preserves endothelium-dependent and nitric oxide (NO)-independent relaxations in arterial preparations from rabbits fed a high-cholesterol diet absence of any cholesterol-lowering action. Rabbits were 0.5% for 12 weeks then with/without 2 mg/kg/d an additional 8 weeks. Plasma total LDL-cholesterol concentrations not affected by treatment. Endothelium-dependent NO-mediated relaxation elicited acetylcholine A23187 both thoracic...
バルサルタン（ディオバン®）は，ノバルティスファーマ社で合成された選択的AT1受容体拮抗薬である．AT1受容体に対する選択性が高く，昇圧因子として作用するAIIに対して競合的に拮抗し，持続的な降圧作用を示す．バルサルタンの降圧作用を，ナトリウム枯渇マーモセットを用いて覚醒下かつ無拘束下で検討すると，バルサルタンの経口投与は心拍数には影響をおよぼすことなく，用量依存的に平均血圧を低下させ，長時間にわたりその作用を持続した．2腎性片側狭窄（2K1C）型高血圧モデルラット，自然発症高血圧ラット（SHR）などの動物モデルにおいても，バルサルタンの単回投与および連続経口投与は用量に依存した持続的な降圧作用を示し，休薬時に血圧のリバウンド現象は観察されなかった．また，脳卒中易発症性SHRおよび急性虚血性心不全モデルラットにおいて，バルサルタンは高血圧に伴う血管肥厚，心肥大，腎障害の発症·進展を有意に抑制した．さらに，高血圧症治療における他剤との併用を考慮し，バルサルタンと利尿降圧薬またはACE阻害薬との併用効果を検討したところ，SHRにおいて，バルサルタンと利尿降圧薬との併用は，バルサルタン...